Trillium Therapeutics to Present at Upcoming Investor Conferences
TORONTO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company’s programs and progress at several upcoming conferences.
-- Ladenburg Thalmann 2018 Healthcare Conference Presenter: Dr. Niclas Stiernholm, Chief Executive Officer Date and Time: October 2, 2018 at 2:30 p.m. EDT Location: Hotel Sofitel, New York City
-- Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology Presenters: Dr. Niclas Stiernholm, Chief Executive Officer and Dr. Robert Uger, Chief Scientific Officer Date and Time: October 3, 2018 at 4:00 p.m. EDT Location: Lotte New York Palace Hotel, New York City
A live audio webcast of the Leerink Partners fireside chat will be available under the investor relations section of Trillium’s website at www.trilliumtherapeutics.com.
About Trillium Therapeutics
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “do not eat” signal that cancer cells frequently use to evade the immune system. Trillium also has a proprietary fluorine-based medicinal chemistry platform that is being used to develop novel compounds directed at undisclosed immuno-oncology targets. For more information, please visit www.trilliumtherapeutics.com
Contact:James ParsonsChief Financial OfficerTrillium Therapeutics Inc. 416-595-0627 x232 email@example.com
Investor and Media Relations:Jessica Tieszen Canale Communications for Trillium Therapeutics 619-849-5385 firstname.lastname@example.org